MedPath

RECKITT BENCKISER LLC

RECKITT BENCKISER LLC logo
🇺🇸United States
Ownership
Subsidiary
Established
1889-01-01
Employees
-
Market Cap
-
Website
http://www.lysol.com

Clinical Trials

15

Active:0
Completed:15

Trial Phases

5 Phases

Phase 1:4
Phase 2:2
Phase 3:4
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials

Phase 1
4 (26.7%)
Phase 3
4 (26.7%)
Not Applicable
3 (20.0%)
Phase 2
2 (13.3%)
Phase 4
2 (13.3%)

Study to Evaluate the Safety and Tolerability of Mucinex™(Guaifenesin) 600 mg Extended-Release Bi-Layer Tablets in the Treatment of Otherwise Healthy Patients With Symptoms of Cough, Thickened Mucus and Chest Congestion

Phase 4
Completed
Conditions
Healthy Subjects
Interventions
Drug: Mucinex™ extended-release (SE)
First Posted Date
2018-10-30
Last Posted Date
2019-03-19
Lead Sponsor
Reckitt Benckiser LLC
Target Recruit Count
552
Registration Number
NCT03725085

Mucinex® ER 600 mg Bi-Layer Tablet Fed and Fasted

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
First Posted Date
2018-08-28
Last Posted Date
2019-03-27
Lead Sponsor
Reckitt Benckiser LLC
Target Recruit Count
36
Registration Number
NCT03649750

Study to Evaluate Drug-drug Interactions of Guaifenesin and Hydrocodone Bitartrate

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
First Posted Date
2018-08-22
Last Posted Date
2019-06-20
Lead Sponsor
Reckitt Benckiser LLC
Target Recruit Count
24
Registration Number
NCT03642873

Study to Evaluate the Pharmacokinetics of Guaifenesin in Adults and Adolescents

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: Children's Mucinex® Grape Flavor
First Posted Date
2018-08-16
Last Posted Date
2019-06-17
Lead Sponsor
Reckitt Benckiser LLC
Target Recruit Count
24
Registration Number
NCT03633448

Study to Evaluate the Pharmacokinetics of Mucinex® 1200 mg Extended-Release Tablet

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
First Posted Date
2018-08-16
Last Posted Date
2019-02-28
Lead Sponsor
Reckitt Benckiser LLC
Target Recruit Count
24
Registration Number
NCT03633487
  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath